Table 4. Univariate and Multivariable Analysis for Overall Survival of Patients with or without Splenomegaly before PSM.
| Clinical variable | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| β | HR (95% CI) | P | β | HR (95% CI) | P | ||
| Age, year | ‒1.648 | 0.993 (0.985–1.001) | 0.099 | ||||
| Sex, male vs. female | 0.137 | 1.019 (0.776–1.34) | 0.891 | ||||
| HBsAg | ‒1.269 | 0.844 (0.65–1.097) | 0.204 | ||||
| TBIL | ‒0.407 | 0.998 (0.99–1.006) | 0.684 | ||||
| DBIL | ‒0.472 | 0.997 (0.985–1.01) | 0.637 | ||||
| ALB | ‒0.518 | 0.995 (0.975–1.015) | 0.605 | ||||
| ALT | ‒0.333 | 1 (0.998–1.001) | 0.739 | ||||
| PT | ‒0.838 | 0.997 (0.99–1.004) | 0.402 | ||||
| AFP | 3.965 | 1 (1.0–1.0) | <0.001 | 1.971 | 1 (1.0–1.0) | <0.001 | |
| Tumor diameter | 2.985 | 1.027 (1.009–1.045) | 0.003 | 1.963 | 1.021 (1–1.043) | 0.05 | |
| Esophageal and gastric varices | ‒0.092 | 0.99 (0.807–1.215) | 0.927 | ||||
| Ascites | ‒0.405 | 0.949 (0.736–1.224) | 0.686 | ||||
| Liver cirrhosis | 1.863 | 1.184 (0.991–1.415) | 0.062 | ||||
| No# of tumor | ‒0.383 | 0.954 (0.751–1.213) | 0.702 | ||||
| PVTT | 1.233 | 1.116 (0.938–1.327) | 0.218 | ||||
| Tumor capsule | ‒6.288 | 0.739 (0.673–0.812) | <0.001 | ‒4.253 | 0.809 (0.734–0.892) | <0.001 | |
| CA199 | 1.013 | 1.001 (0.999–1.002) | 0.311 | ||||
| CEA | 2.913 | 1.026 (1.008–1.044) | 0.004 | 3.619 | 1.03 (1.013–1.046) | <0.001 | |
| AST | 4.003 | 1.004 (1.002–1.006) | <0.001 | 1.838 | 1.002 (1–1.004) | 0.066 | |
| Thickness of splenic hilum | 5.219 | 1.22 (1.132–1.315) | <0.001 | 2.894 | 1.129 (1.04–1.226) | 0.004 | |
| PLT | 0.268 | 1 (0.999–1.001) | 0.789 | ||||
PSM, propensity score matching; HBsAg, Hepatitis B surface antigen; TBIL, Total Bilirubin; DBIL, Direct Bilirubin; ALB, Albumin; ALT, Alanine Aminotransferase; PT, Prothrombin time; AFP, α-fetoprotein; PVTT, portal vein tumor thrombus; CA199, Carbohydrate Atigen 19-9; CEA, Carcinoembryonic antigen; AST, Aspartate Aminotransferase; PLT, Platelet.